ArticleDiscover oncology2025
Neddylation related gene signature for prognostic biomarkers in colorectal cancer with integrated bioinformatics and experimental analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of neddylation in colorectal cancer (CRC) is increasingly recognized as a significant factor. Our study employed bioinformatics analysis to investigate the functions of neddylation-related genes in CRC.
methodsTranscriptome data from multiple public databases were integrated and analyzed using a comprehensive bioinformatics approach, including differential expression analysis, weighted gene co-expression network analysis, and machine learning tactics to identify prognostic genes. These genes were then implemented to establish a risk prediction model. Single-cell RNA sequencing (scRNA-seq) was utilized to reveal the distribution and interactions of various cell types. The characteristics of immune cell infiltration were assessed by immune infiltration analysis. Finally, the functional roles of the prognostic gene were validated through the wound healing assay, cell counting kit-8, and transwell assay.
resultsThree genes—CCNF, ANKRD13D, and PSMA7—were identified as prognostic markers. The risk prediction model built on these genes demonstrated modest predictive performance, with the area under the curve values exceeding 0.6 at 3, 5, and 7 years. Immune infiltration analysis showed that the infiltration levels of 15 immune cells, including plasmacytoid dendritic cells and eosinophil, were markedly higher in the high-risk cohort. Furthermore, scRNA-seq data indicated that M1 macrophages exhibited higher scores for the neddylation gene set in CRC. Experimental validation demonstrated that knockdown of ANKRD13D inhibits cell proliferation, migration, and invasion.
conclusionThis study established a preliminary prognostic risk model based on CCNF, ANKRD13D, and PSMA7, which exhibits exploratory predictive value for CRC prognosis. These results identified CCNF, ANKRD13D, and PSMA7 as potential candidate biomarkers for prognostic assessment in CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.